
About Mitchell
Dr. Mitchell Finer serves as President of Research and Development of ElevateBio as well as CEO of Life Edit Therapeutics, an ElevateBio company developing a next-generation gene editing platform. He is a co-founder of ElevateBio and serves on its Board of Directors. Dr. Finer also serves as an executive partner at MPM Capital.
Formerly he served as Chief Scientific Officer of Bluebird Bio, where he led the team that conceived of and developed three approved products: Abecma for the treatment of multiple myeloma, Zynteglo for the treatment of beta thalassemia and Skysona for the treatment of childhood cerebral adrenoleukodystrophy. He has served as founder, executive officer or board member at multiple cell therapy, gene therapy and regenerative medicine companies over the last 33 years, including Adverum Biotechnologies, Bluebird Bio, Coda Biotherapeutics, Cell Genesys, the Gencell division of Aventis Pharma (now Sanofi), Genteric, Inc., Intracel Corporation, Novacell (now Viacyte, acquired by Vertex), Oncorus, Inc., Semma Therapeutics, Turmeric Acquisition Holdings, and TCR2 Therapeutics.
Education and Accomplishments
Dr. Finer has been named inventor on 15 issued U.S. patents. He received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.